HLB Life Science said on the 22nd it will issue 15.7 billion won in exchangeable bonds (EB). Exchangeable bonds are bonds issued with stocks held by corporations and other assets as collateral. It is convenient for corporations because they can raise funds, but when the buyer of the bond exercises the exchange right, it has the same effect as selling shares on the market.
HLB Life Science will use 278,551 shares (0.21%) of parent HLB as the exchange target. The exchange price is 56,363 won, 10% higher than the previous share price. The exchange request period is from Mar. 7, 2026, to Jan. 20, 2029. Reflecting investor demands, the timing for exercising the early redemption right was set at 18 months by agreement.
The company plans to improve its financial structure by issuing exchangeable bonds. An HLB Life Science official said, "We will strengthen the foundation for generating operating profit."